Valuing Bicoon Biologics at Rs 21450 cr
Biocon announced that the Board of its subsidiary Biocon Biologics India has approved a primary equity investment by True North. As per the terms of the proposed agreement, True North will invest Rs 536.25 crore that will eventually translate to a 2.44% minority stake in the biosimilars business post all restructuring, including the filed merger of Biocon Research with Biocon Biologics, valuing Biocon Biologics at Rs 21,450 crore or ~USD 3 billion on a pre-money equity basis.The transaction is subject to standard condition precedents including regulatory approvals. Post the completion of this transaction, Biocon will hold 96.07% stake in Biocon Biologic
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
